Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 5/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | AURKA | O14965 | 3/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388707 | 0.69 | AURKA (0.35) | CDK5CDK5R1GSK3BAURKAGSK3A | |
| SCHEMBL12388706 | 0.66 | CYP2C8 (0.33) | AURKA | |
| SCHEMBL12388704 | 0.62 | ALDH1A1 (0.37) | — | |
| SCHEMBL30577511 | 0.58 | AURKA (0.45) | AURKA | |
| SCHEMBL14452879 | 0.58 | HTR2C (0.33) | — | |
| SCHEMBL12436479 | 0.57 | CYP2A6 (0.37) | — | |
| SCHEMBL9963984 | 0.57 | PTPRC (0.46) | — | |
| SCHEMBL2484666 | 0.56 | AURKA (0.60) | AURKA | |
| SCHEMBL13600283 | 0.56 | KDM4E (0.41) | — | |
| SCHEMBL30273079 | 0.56 | DAO (0.43) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | CDK5 300/4885CDK5R1 538/4885CCNB2 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.